1	El	el	DA0MS0	-	-	0-2	760(1)_ANS_clinical_caseMIR	SENT1	-	-
2	tocilizumab	tocilizumab	NC00SC0	C1609165	producto#sustancia	3-14	760(1)_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
3	se	se	P00CN000	-	-	15-17	760(1)_ANS_clinical_caseMIR	SENT1	-	-
4	ha	haber	VAIP3S0	-	-	18-20	760(1)_ANS_clinical_caseMIR	SENT1	-	-
5	mostrado	mostrar	VMP00SM	-	-	21-29	760(1)_ANS_clinical_caseMIR	SENT1	-	-
6	eficaz	eficaz	NC00SC0	C1704419	calificador	30-36	760(1)_ANS_clinical_caseMIR	SENT1	-	-
7	en	en	SPS00	C1720294#C0332285	calificador#atributo	37-39	760(1)_ANS_clinical_caseMIR	SENT1	-	-
8	reducir	reducir	VMN0000	-	-	40-47	760(1)_ANS_clinical_caseMIR	SENT1	-	-
9	las	el	DA0FP0	-	-	48-51	760(1)_ANS_clinical_caseMIR	SENT1	-	-
10	recidivas	recidiva	NCFP000	C0034897#C2945760#C0035020	calificador	52-61	760(1)_ANS_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-
11	y	y	CC	C1706368	calificador	62-63	760(1)_ANS_clinical_caseMIR	SENT1	-	-
12	la	el	DA0FS0	-	-	64-66	760(1)_ANS_clinical_caseMIR	SENT1	-	-
13	dosis	dosis	NCFN000	-	-	67-72	760(1)_ANS_clinical_caseMIR	SENT1	-	-
14	acumulada	acumular	VMP00SF	-	-	73-82	760(1)_ANS_clinical_caseMIR	SENT1	-	-
15	de	de	SPS00	C0332285	atributo	83-85	760(1)_ANS_clinical_caseMIR	SENT1	-	-
16	prednisona	prednisona	NCFS000	C0032952	sustancia	86-96	760(1)_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
17	en	en	SPS00	C1720294#C0332285	calificador#atributo	97-99	760(1)_ANS_clinical_caseMIR	SENT1	-	-
18	más	más	RG	C0205172	calificador	100-103	760(1)_ANS_clinical_caseMIR	SENT1	-	-
19	del	del	SP+DA	-	-	104-107	760(1)_ANS_clinical_caseMIR	SENT1	-	-
20	50	50	Z	-	-	108-110	760(1)_ANS_clinical_caseMIR	SENT1	-	-
21	%	%	Ft	-	-	111-112	760(1)_ANS_clinical_caseMIR	SENT1	-	-
22	de	de	SPS00	C0332285	atributo	113-115	760(1)_ANS_clinical_caseMIR	SENT1	-	-
23	los	el	DA0MP0	-	-	116-119	760(1)_ANS_clinical_caseMIR	SENT1	-	-
24	pacientes	paciente	NCCP000	C0030705	persona	120-129	760(1)_ANS_clinical_caseMIR	SENT1	-	-
25	.	.	Fp	-	-	130-131	760(1)_ANS_clinical_caseMIR	SENT1	-	-

